profit from every $100 of sales.
$0$100
Nyxoah
$0.90-0.53% today
-69.6% in 1 year
1-year low $0.811-year high $2.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Nyxoah sold, what it kept, and what it did with the cash.
Sales went from €3.08 million in 2022 to €10.0 million in 2025, with -€90.1 million of profit last year.
SalesProfit
Nyxoah vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Nyxoah | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.0× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Nyxoah's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 3 | 4 | 5 | 10 | |
| 2 | 3 | 3 | 6 | |
| -32 | -45 | -59 | -83 | |
| -28 | -42 | -53 | -83 | |
| -31 | -43 | -59 | -90 | |
| -1.21 | -1.55 | -1.81 | -2.36 | |
| 62.7% | 61.9% | 65.7% | 63.1% | |
| -1,053.8% | -1,037.3% | -1,300.8% | -827.8% | |
| -1,012.5% | -993.8% | -1,310.2% | -899.1% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 146 | 124 | 158 | 118 |
| Cash | 18 | 22 | 34 | 30 |
| Total debt | 12 | 13 | 23 | 40 |
| Total liabilities | 26 | 26 | 45 | 69 |
| 120 | 98 | 113 | 49 | |
| 26 | 28 | 33 | 38 | |
| -17.8% | -31.7% | -32.3% | -77.0% | |
| -26.0% | -44.1% | -52.3% | -183.4% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -29 | -45 | -49 | -69 | |
| 16 | 11 | 6 | 4 | |
| -45 | -56 | -55 | -73 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| 3 | 3 | 4 | 5 |
Valuation
- –
- –
- –
- 2.3×
- 8.2×
- –
- –
- -88.2%
- -109.3%
- 0.0%
Profitability
- 63.1%
- -827.8%
- -899.1%
- -809.5%
- -90.7%
- -44.4%
- -135.3%
- -76.1%
- -121.7%
- 428.0%
Growth
- +48.1%
- –
- −23.5%
- –
- +12.5%
Financial health
- –
- 0.86
- 35.5%
- -16.2×
- 1.25
- 1.16
- 0.08
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 947
Top 13%of 866
Bottom 1%of 985
What analysts expect
- Average price target
- $8.50
- Range
- $8.00 – $9.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.43 | -0.54 | +20.4% |
| Mar 19, 2026 | -0.68 | -0.65 | −4.6% |
| Nov 13, 2025 | -0.74 | -0.61 | −21.3% |
| Aug 18, 2025 | -0.63 | -0.62 | −1.6% |
| May 14, 2025 | -0.63 | -0.49 | −28.6% |
| Mar 13, 2025 | -0.49 | -0.46 | −6.5% |
| Nov 6, 2024 | -0.55 | -0.46 | −19.6% |
| Aug 6, 2024 | -0.46 | -0.45 | −2.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
32No pass
Philip Fisher
52No pass
Peter Lynch
89Pass
Joel Greenblatt
0No pass
Charlie Munger
38No pass
Terry Smith
40No pass
Questions about Nyxoah
Is Nyxoah a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nyxoah AI analysis
What does Nyxoah do?
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It is in Medical - Instruments & Supplies.
Does Nyxoah pay a dividend?
No. Nyxoah does not pay a dividend at the moment.
Is Nyxoah stock halal?
No. Nyxoah does not pass our halal screen: its debt is 49% of its market value, at or above the 33% limit. How we check
How has Nyxoah stock done over the past year?
Down 69.6% over the past twelve months, to $0.90. It traded between $0.81 and $2.95 and is 69.6% below its high.
Who are Nyxoah's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Nyxoah's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.